The new patent is for L-ergothioneine's support of eye health.
NNB Nutrition (Nanjing, China) has applied for a new patent in China for its L-ergothioneine ingredients. The filing is for its trademarked MitoPrime ingredient was for the amelioration of age-related visual degeneration, which is the leading cause of vision loss. L-ergothioneine is known to be concentrated in the eyes, particularly the retina. A naturally water-soluble amino acid, L-ergothioneine has antioxidant properties that help protect the eyes from damage by scavenging chronic reactive oxygen radicals (ROS), reducing intracellular ROS production, and inhibiting oxidation-induced the epithelial-to-mesenchymal transition (EMT) in the retina.
“MitoPrime with high purity was produced by a proprietary natural fermentation process. Also, it can be made in nutritional drink, food, beverage, sugar, capsule, tablet, powder and so on.” NNB Nutrition said in a press release.
According to NNB, ergothioneine is unique because it is the only micro-nutrient that possesses its own dedicated nutrient transport protein known as ETT. NNB has completed four clinical/ex-vivo studies that investigate the benefits of L-ergothioneine, as part of its series of “12 Investigative Clinical Trials with L-ergothioneine.”
“We began our series of ‘12 Investigative Clinical Trials with L-Ergothioniene’ in the third quarter of 2020,” said Kylin Liao, NNB’s founder, in a press release. “We will continue our investigative pursuit into Ergothioneine’s panoply of benefits including heart health, cognitive improvement, immune health and mitigating the long term effects of extreme viruses such as COVID-19.”
Remaining eight studies looking into the ingredient’s benefits as both a therapeutic ingestible and topical treatment for dermatological applications were scheduled to be completed between August 18, 2021 and February 21, 2022.
This article was updated on 9/3/21 at 9:08 AM